FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer

Project Oncology® - A podcast by ReachMD

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer. Released July 25, 2017